Sean Delshad, MD, MBA, on PPI-Refractory GERD


In this podcast, Sean Delshad, MD, MBA, discusses the true extent of gastroesophageal reflux disease in the United States, the proportion of patients with GERD that is refractory to proton pump inhibitors, and prospects for new treatments of this common disease. Read the full transcript here.


  • Delshad SD, Almario C2, Chey WD, et al. Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms. Gastroenterology. 2020;158(5):1250-1261.
  • Moayyedi P, Eikelboom JW, Bosch J, et al; COMPASS Investigators. Safety of proton pump inhibitors based on a large, multiyear, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682-691.
  • Vaezi MF, Fass R, Vakil N et al. IW-3718 reduces heartburn severity in patients with refractory gastroesophageal reflux disease in a randomized trial. Published online February 21, 2020. Gastroenterology.
  • Lee JK, Merchant SA, Schneider JL et al. Proton pump inhibitor use and the risk of colorectal, liver, and pancreatic cancers in a community-based population. Am J Gastroenterol. 2020;115(5):706-715. doi: 10.14309/ajg.0000000000000591


Sean Delshad, MD, MBA, is a clinical researcher from the Cedars-Sinai Center for Outcomes Research and Education and faculty member of the David Geffen School of Medicine at UCLA in Los Angeles, California.